QUANTUMZYME CORP (QTZM) Financials
Newest figures come from the 10-Q for Q3 FY2026, filed Jun 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the QTZM SEC filings page.
QUANTUMZYME CORP (QTZM) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Quantumzyme’s dominant mechanic is a liability-heavy balance sheet, with historical operations also relying on external funding.
The latest balance sheet combines negative equity with a near-zero current ratio, so obligations overwhelm recorded assets and short-term resources rather than merely creating a thin liquidity cushion. Between FY2024 and FY2025, liabilities increased while assets contracted, reinforcing that the deterioration is structural across the reported year-end snapshots.
Historical earnings quality was weak: FY2017’s
Operating cash flow also deteriorated from
Financial Health Signals
QUANTUMZYME CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
QUANTUMZYME CORP generated $0 in revenue in Q3 2026.
QUANTUMZYME CORP earned $0.00 per diluted share (EPS) in Q3 2026. Against the prior quarter it is up 100.0%.
Not reported for Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
QUANTUMZYME CORP held $59 in cash as of Q3 2026; long-term debt is not reported for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
None of these metrics is reported for Q3 2026.
Capital Allocation
None of these metrics is reported for Q3 2026.
QTZM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K/A |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | $3K | $2K | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | -$25K | -$61K | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $5K | $5K | N/A |
| Income Tax | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A | -$30K-398.3% | -$66K+2.9% | N/A |
| EPS (Basic) | N/A | N/A | N/A | N/A | $0.00 | N/A | N/A | N/A |
| EPS (Diluted) | $0.00 | -$0.12 | $0.00 | -$0.01 | $0.00 | $0.00 | $0.00 | N/A |
| Diluted Shares (Avg) | 35M0.0% | 35M0.0% | 39M+12.1% | N/A | 35M | 35M | 35M | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, EBITDA.
QTZM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K/A |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $59-89.9% | $59 | $184 | $584-94.2% | $584 | N/A | N/A | $10K |
| Current Assets | $59-89.9% | $59 | $184 | $584-94.2% | $584 | N/A | N/A | $10K |
| Cash & Equivalents | $59-89.9% | $59-96.6% | $184-96.4% | $584 | $584 | $2K | $5K | $0 |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $443K+10.0% | $418K | $491K | $441K+50.5% | $403K | N/A | N/A | $293K |
| Current Liabilities | $443K+10.0% | $418K | $491K | $441K+50.5% | $403K | N/A | N/A | $293K |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | N/A | N/A | $0 |
| Total Equity | -$443K-10.1% | -$418K-12.1% | -$491K-42.9% | -$441K-55.6% | -$403K-108.4% | -$373K-107.7% | -$343K-107.1% | -$283K |
| Retained Earnings | -$10.0M-79.4% | -$10.0M | -$5.7M | -$5.6M-3.7% | -$5.6M | N/A | N/A | -$5.4M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
QTZM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
QTZM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Debt-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$441K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where QUANTUMZYME CORP Ranks
Frequently Asked Questions
What is QUANTUMZYME CORP's annual revenue?
QUANTUMZYME CORP (QTZM) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
What are QUANTUMZYME CORP's total assets?
QUANTUMZYME CORP (QTZM) had $584 in total assets as of fiscal year 2025, including both current and long-term assets.
What is QUANTUMZYME CORP's current ratio?
QUANTUMZYME CORP (QTZM) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Why is QUANTUMZYME CORP's debt-to-equity ratio negative or not reported?
QUANTUMZYME CORP (QTZM) has negative shareholder equity of -$441K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.